Skip to content

Effect of Q10 on multiple sclerosis patients

Effect of coenzyme Q10 on inflammatory factors in multiple sclerosis patients.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT138905172602N4
Enrollment
50
Registered
2011-08-05
Start date
2011-09-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Q10 supplement (500mg/day) for 90 days. Intervention 2: Control group: 2 capsules/day including dietary fiber.
Treatment - Drugs
Placebo
Intervention group: Q10 supplement (500mg/day) for 90 days
Control group: 2 capsules/day including dietary fiber

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 51 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 18-51 years, able to provide informed consent and diagnosed with relapsing remitting MS. Exclusion criteria: MS exacerbation during the study, systemically administered corticosteroids during the study , pregnant or breast-feeding , other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus and other autoimmune disease) that might increase the risk of subject experiencing adverse events. Consumption of vitamin, mineral and antioxidant supplement 30 days before study entry, Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study and compliance less than 70%.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
TGF-B. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.;Serum TNF-a concentration. Timepoint: 12 weeks after the intervention. Method of measurement: labratory kit.;IL-4. Timepoint: 12 weeks after the intervention. Method of measurement: ELYSA.;IL-6. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.;MMP-9. Timepoint: 12 weeks after the intervention. Method of measurement: ELISA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shahriar Eghtesadi

School of Health, tehran University of Medical Sciences

egtesadi@iums.ac.ir, eghtesadi@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026